Topical and Intralesional Therapies for in-Transitmelanoma
Open Access
- 2 September 2019
- journal article
- review article
- Published by Taylor & Francis in Melanoma Management
- Vol. 6 (3) , MMT23
Abstract
This report surveys the role of topical and intralesional agents in the management of in-transit melanoma. The extent and progression of in-transit disease is highly variable and many patients can ...Keywords
This publication has 40 references indexed in Scilit:
- Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast CancerPLOS ONE, 2013
- Aldara activates TLR7-independent immune defenceNature Communications, 2013
- High response rate after intratumoral treatment with interleukin‐2Cancer, 2010
- Topical diphencyprone immunotherapy for cutaneous metastatic melanomaAustralasian Journal of Dermatology, 2009
- Chemoablation of metastatic melanoma using intralesional Rose BengalMelanoma Research, 2008
- Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673)Cancer, 2004
- Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guérin therapy for locally metastatic melanomaCancer Immunology, Immunotherapy, 1991
- Risks of BCG intralesional therapy: An experience with melanomaJournal of Surgical Oncology, 1977
- BCG Immunotherapy in Patients With Malignant MelanomaArchives of Surgery, 1976
- BCG lmmunotherapy of Malignant MelanomaAnnals of Surgery, 1974